A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.
A Phase Ib/II Clinical Study to Evaluate the Efficacy and Safety of TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Participants With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.
To assess the safety and preliminary efficacy of TQB2930 and chemotherapy with or without bevacizumab in sparticipants with HER2-Abnormally Expressed locally advanced or metastatic colorectal cancer (CRC).
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
- Legemiddel: TQB2930 injection +(Oxaliplatin for injection + Capecitabine tablets)/( Irinotecan hydrochloride injection+ Capecitabine tablets)+Bevacizumab injection
- Legemiddel: TQB2930 injection +(Oxaliplatin for injection + Capecitabine tablets)/( Irinotecan hydrochloride injection+ Capecitabine tablets)
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Fase 2
- Fase 1
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Ruihua Xu, Doctor
- Telefonnummer: 020-87343468
- E-post: xurh@syscc.org.cn
Studiesteder
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina, 100034
- Har ikke rekruttert ennå
- Peking University First Hospital
-
Ta kontakt med:
- Shikai Wu, Doctor
- Telefonnummer: 15810037307
- E-post: Skywu4923@sina.com
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, Kina, 400016
- Har ikke rekruttert ennå
- The First Affiliated Hospital of Chongqing Medical University
-
Ta kontakt med:
- Tao Zhang, Doctor
- Telefonnummer: 13708311156
- E-post: tumorzzt@163.com
-
-
Gansu
-
Lanzhou, Gansu, Kina, 730050
- Har ikke rekruttert ennå
- Gansu Provincial Tumor Hospital
-
Ta kontakt med:
- Zhihu Li, Master
- Telefonnummer: 18993042850
- E-post: 245698692@qq.com
-
-
Guangdong
-
Foshan, Guangdong, Kina, 528000
- Har ikke rekruttert ennå
- The First People's Hospital of Foshan
-
Ta kontakt med:
- Wei Wang, Doctor
- Telefonnummer: 18038863618
- E-post: wangwei@fsyyy.com
-
Guangzhou, Guangdong, Kina, 510060
- Rekruttering
- Sun Yat-sen University Cancer Center
-
Ta kontakt med:
- Ruihua Xu, Doctor
- Telefonnummer: 020-87343468
- E-post: xurh@syscc.org.cn
-
Guangzhou, Guangdong, Kina, 510000
- Har ikke rekruttert ennå
- The Sixth Affiliated Hospital, Sun Yat-sen University
-
Ta kontakt med:
- Yanhon Den, Doctor
- Telefonnummer: 13925106525
- E-post: dengyanh@mail.sysu.edu.cn
-
-
Guangxi
-
Nanning, Guangxi, Kina, 530000
- Har ikke rekruttert ennå
- Guangxi Zhuang Autonomous Region Cancer Hospital
-
Ta kontakt med:
- Rong Liang, Doctor
- Telefonnummer: 18677070811
- E-post: 53371159@qq.com
-
-
Guizhou
-
Zunyi, Guizhou, Kina, 563000
- Rekruttering
- The Affiliated Hospital of Zunyi Medical University
-
Ta kontakt med:
- Jiwei Wang, Doctor
- Telefonnummer: 18013964231
- E-post: zmu_wangjw@163.com
-
-
Heilongjiang
-
Harbin, Heilongjiang, Kina, 150000
- Har ikke rekruttert ennå
- Harbin Medical University Cancer Hospital
-
Ta kontakt med:
- Tongsen Zheng, Doctor
- Telefonnummer: 15134569619
- E-post: zhengtongsen@126.com
-
Ta kontakt med:
- Yuxian Bai, Doctor
- Telefonnummer: 13945095085
- E-post: bai_yuxian@126.com
-
Qiqihar, Heilongjiang, Kina, 161005
- Har ikke rekruttert ennå
- Qiqihar First Hospital
-
Ta kontakt med:
- Xiyuan Sun, Doctor
- Telefonnummer: 13945258792
- E-post: sunxiyuan2004@126.com
-
-
Henan
-
Zhengzhou, Henan, Kina, 450000
- Har ikke rekruttert ennå
- Henan Cancer Hospital
-
Ta kontakt med:
- Ying Liu, Doctor
- Telefonnummer: 13783604602
- E-post: yaya7207@126.com
-
Zhengzhou, Henan, Kina, 450000
- Har ikke rekruttert ennå
- The Third People's Hospital of Zhengzhou
-
Ta kontakt med:
- HaiCun Wang, Master
- Telefonnummer: 13803833783
- E-post: whc1975@126.com
-
Zhengzhou, Henan, Kina, 450000
- Har ikke rekruttert ennå
- The first affiliated hospital of Zhengzhou university
-
Ta kontakt med:
- Yongxu Jia, Doctor
- Telefonnummer: 15237128281
- E-post: fccjiayx@zzu.edu.cn
-
-
Hubei
-
Jingzhou, Hubei, Kina, 434099
- Har ikke rekruttert ennå
- Jingzhou First People's Hospital
-
Ta kontakt med:
- Yan Hu, Master
- Telefonnummer: 18163137369
- E-post: helensparkle@163.com
-
Wuhan, Hubei, Kina, 430022
- Har ikke rekruttert ennå
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Ta kontakt med:
- Hongli Liu, Doctor
- Telefonnummer: 13995680822
- E-post: hongliliu@hust.edu.cn
-
-
Hunan
-
Changsha, Hunan, Kina, 410013
- Rekruttering
- Hunan Cancer Hospital
-
Ta kontakt med:
- Yi He, Doctor
- Telefonnummer: 18692237222
- E-post: heyi@hnca.org.cn
-
-
Jiangsu
-
Nanjing, Jiangsu, Kina, 210008
- Rekruttering
- Nanjing Drum Tower Hospital
-
Ta kontakt med:
- Yudong Qiu, Doctor
- Telefonnummer: 13951806490
- E-post: yudongqiu510@163.com
-
Nanjing, Jiangsu, Kina, 210009
- Rekruttering
- Zhongda Hospital Southeast University
-
Ta kontakt med:
- CaiLian Wang, Doctor
- Telefonnummer: 13851756378
- E-post: wangcailian65@hotmail.com
-
Nanjing, Jiangsu, Kina, 210000
- Har ikke rekruttert ennå
- Jiangsu Provincial Cancer Hospital
-
Ta kontakt med:
- Yuanhua Liu, Doctor
- Telefonnummer: 13305180356
- E-post: yuanhualiu02@hotmail.com
-
-
Jiangxi
-
Nanchang, Jiangxi, Kina, 330000
- Har ikke rekruttert ennå
- Jiangxi Provincal People's Hospital
-
Ta kontakt med:
- Weirong Yao, Doctor
- Telefonnummer: 13907002901
- E-post: 13907002901@126.com
-
-
Jilin
-
Changchun, Jilin, Kina, 130021
- Har ikke rekruttert ennå
- Jilin Cancer Hospital
-
Ta kontakt med:
- Hongxia Cui, Master
- Telefonnummer: 13504436090
- E-post: 2503074283@qq.com
-
Changchun, Jilin, Kina, 130021
- Har ikke rekruttert ennå
- The first hospital of Jilin University
-
Ta kontakt med:
- Tingting Liang, Doctor
- Telefonnummer: 15804303776
- E-post: liangting2006@163.com
-
-
Liaoning
-
Shenyang, Liaoning, Kina, 110000
- Rekruttering
- Liaoning Cancer Hospital & Institute
-
Ta kontakt med:
- Jingdong Zhang, Doctor
- Telefonnummer: 18040007878
- E-post: 13804027878@163.com
-
-
Shaanxi
-
Xi'an, Shaanxi, Kina, 710000
- Har ikke rekruttert ennå
- The First Affiliated Hospital of Xi'an Jiaotong University Medical College
-
Ta kontakt med:
- Aili Suo, Doctor
- Telefonnummer: 18991232561
- E-post: Ailisuo@mail.xjtu.edu.cn
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina, 200127
- Rekruttering
- Renji Hospital, Shanghai Jiao Tong University School of Medicine
-
Ta kontakt med:
- XiuYing Xiao, Doctor
- Telefonnummer: 13564579313
- E-post: xiaoxiuying2002@163.com
-
-
Shanxi
-
Xi’an, Shanxi, Kina, 710000
- Har ikke rekruttert ennå
- The Second Affiliated Hospital of Air Force Medical University
-
Ta kontakt med:
- Haichuan Su, Doctor
- Telefonnummer: 18629190366
- E-post: cntdgcp@163.com
-
Xi’an, Shanxi, Kina, 710000
- Har ikke rekruttert ennå
- The First Affiliated Hospital of Air Force Medical University
-
Ta kontakt med:
- Yongzhan Nie, Doctor
- Telefonnummer: 15091520001
- E-post: nieyongzhan@qq.com
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Kina, 300202
- Rekruttering
- Tianjin Medical University Cancer Institute & Hospital
-
Ta kontakt med:
- Zhanyu Pan, Master
- Telefonnummer: 18622221256
- E-post: tjpanzy@126.com
-
Tianjin, Tianjin Municipality, Kina, 300121
- Har ikke rekruttert ennå
- Tianjin Union Medical Center
-
Ta kontakt med:
- Mingqing Zhang, Doctor
- Telefonnummer: 15122875158
- E-post: zmq1003@163.com
-
-
Xinjiang
-
Ürümqi, Xinjiang, Kina, 830054
- Har ikke rekruttert ennå
- Xinjiang Medical University Affiliated Tumor Hospital
-
Ta kontakt med:
- YanLi Qu, Master
- Telefonnummer: 18160627963
- E-post: quyanli73@163.com
-
-
Zhejiang
-
Lishui, Zhejiang, Kina, 323000
- Rekruttering
- Lishui Municipal Central Hospital
-
Ta kontakt med:
- Yanru Xie, Master
- Telefonnummer: 13567615770
- E-post: 43437677@qq.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Participants voluntarily participate in this study, sign the informed consent form, and have good compliance
- Age: 18-75 years (including the boundary when signing the informed consent form)
- Eastern Cooperative Oncology Group (ECOG) score: 0-1
- Expected survival of more than 3 months
- Unresectable locally advanced or metastatic colorectal cancer diagnosed by histopathology/cytology
- HER2-Abnormally Expressed tested
- Presence of at least one measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
- Participants should agree to use contraception during the study and for 6 months after the end
Exclusion Criteria:
- Participants with previously confirmed Microsatellite Instability Microsatellite Instability-High Deficient Mismatch Repair (MSI-H/dMMR)
- Presence of conditions affecting intravenous, venous blood sampling, or multiple factors affecting oral medications
- Active inflammatory bowel disease within 28 days prior to first dose
- Other malignancies within 5 years prior to the first dose or currently suffering from other malignancies
- Unresolved toxicity greater than CTCAE Grade 1 due to any prior therapy
- Major surgical treatment, significant traumatic injury within 28 days prior to the first dose or anticipation of major surgery during study treatment
- Had wounds or fractures that had not been healed for a long time
- Cerebrovascular accident, deep venous thrombosis and pulmonary embolism within 6 months prior to the first dose
- Patients with a history of psychotropic substance abuse who cannot quit or have mental disorders
- Participants with any severe and/or uncontrolled disease
- Known tumor-related carcinomatous meningitis with symptoms of brain metastases or symptom control for less than 4 weeks
- Patients with imaging suggestive of tumor invasion of major blood vessels or fatal massive hemorrhage due to tumor rupture or invasion of major blood vessels judged by the investigator to be very likely to occur during the study
- Failure to control serous effusions requiring repeated drainage
- Local radiotherapy or 4. Bone marrow irradiation > 30% for bone metastasis before the first medication
- Known tumor-related spinal cord compression, weight-bearing bone pathological fracture, extensive bone metastasis, or uncontrollable tumor bone metastasis-related pain
- Patients who have received chemotherapy, targeted therapy, immunotherapy or other systemic anti-tumor drug therapy before the first medication;
- Received Chinese patent medicine treatment with anti-tumor indications in the package insert of National Medical Products Administration (NMPA) approved drugs before study treatment
- History of live attenuated vaccination before the first dose or planned live attenuated vaccination during the study;
- Previous history of severe allergy of unknown origin
- According to the investigator's judgment, there are concomitant diseases that seriously endanger the participants' safety or affect the completion of the study, or the participant is considered unsuitable for other reasons
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: TQB2930 injection +chemotherapy + Bevacizumab injection
|
TQB2930 enhances the binding to HER2 protein on the surface of tumor cells and increases HER2 internalization by simultaneously targeting ECD2 and ECD4, two non-overlapping epitopes of HER2 protein, which in turn more effectively down-regulates HER2 protein on the surface of tumor cells and dually blocks HER2 signaling. Oxaliplatin can block DNA replication and transcription and induce tumor cell apoptosis. Irinotecan hydrochloride injection inhibits topoisomerase-I via its active metabolite SN-38, prevents religation of DNA single-strand breaks, causes irreversible DNA double-strand damage and induces tumor cell apoptosis. Capecitabine inhibits thymidylate synthase (TS) and interferes with DNA synthesis. Bevacizumab blocks VEGF binding to receptors and inhibits tumor angiogenesis. |
|
Aktiv komparator: TQB2930 injection +chemotherapy
|
TQB2930 enhances the binding to HER2 protein on the surface of tumor cells and increases HER2 internalization by simultaneously targeting ECD2 and ECD4, two non-overlapping epitopes of HER2 protein, which in turn more effectively down-regulates HER2 protein on the surface of tumor cells and dually blocks HER2 signaling. Oxaliplatin can block DNA replication and transcription and induce tumor cell apoptosis. Irinotecan hydrochloride injection inhibits topoisomerase-I via its active metabolite SN-38, prevents religation of DNA single-strand breaks, causes irreversible DNA double-strand damage and induces tumor cell apoptosis. Capecitabine inhibits thymidylate synthase (TS) and interferes with DNA synthesis. |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Recommended Phase 2 Dose
Tidsramme: Baseline up to 21 days
|
It refers to the safe and effective dose range that can be used for phase II study determined through phase I clinical trial. |
Baseline up to 21 days
|
|
Adverse event (AE)
Tidsramme: From the participants signing of the informed consent form to 28 days after the last dose or the start of new anti-tumor therapy (whichever occurs first)
|
Incidence and severity of adverse events. |
From the participants signing of the informed consent form to 28 days after the last dose or the start of new anti-tumor therapy (whichever occurs first)
|
|
Objective Response Rate
Tidsramme: Baseline up to 24 months
|
The proportion of participants achieving complete response and partial response among the total evaluable cases. |
Baseline up to 24 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Half-life
Tidsramme: Baseline up to 24 months
|
The time it takes for the concentration of a drug in the body (usually the plasma concentration) to decrease to half of its initial value. |
Baseline up to 24 months
|
|
Plasma concentration-time profiles
Tidsramme: Baseline up to 24 months
|
Total area covered under the curve plotted with time as X-axis and plasma concentration as Y-axis. |
Baseline up to 24 months
|
|
Apparent clearance
Tidsramme: Baseline up to 24 months
|
The rate at which the drug is cleared from the body. |
Baseline up to 24 months
|
|
Apparent terminal volume of distribution
Tidsramme: Baseline up to 24 months
|
Describe the drug distribution in the body. |
Baseline up to 24 months
|
|
Trough plasma concentration
Tidsramme: Baseline up to 24 months
|
Minimum plasma drug concentration level at the end of the dosing interval (before the next dosing). |
Baseline up to 24 months
|
|
Disease Control Rate
Tidsramme: Baseline up to 24 months
|
The percentage of participants with a complete response, partial response, or stable disease as determined by RECIST 1.1. |
Baseline up to 24 months
|
|
Duration Of Response
Tidsramme: Baseline up to 24 months
|
The time from the first assessment of the tumor as a complete response or partial response to the first occurrence of disease progression or death from any cause. |
Baseline up to 24 months
|
|
Progression Free Survival
Tidsramme: Baseline up to 24 months
|
Progression Free Survival (PFS) is defined as the length of time from the start of treatment until the disease progresses or the patient dies from any cause. |
Baseline up to 24 months
|
|
Overall Survival
Tidsramme: Baseline up to 24 months
|
The time from the start of initial treatment to death from any cause. |
Baseline up to 24 months
|
|
Anti-Drug Antibodies (ADA) incidence
Tidsramme: Baseline up to 24 months
|
Proportion of anti-drug antibody produced in the population of patients using the drug. |
Baseline up to 24 months
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Neoplasmer etter nettsted
- Neoplasmer
- Tarmsykdommer
- Gastrointestinale neoplasmer
- Neoplasmer i fordøyelsessystemet
- Sykdommer i fordøyelsessystemet
- Gastrointestinale sykdommer
- Intestinale neoplasmer
- Rektale sykdommer
- Kolonsykdommer
- Kolorektale neoplasmer
- Terapeutikk
- Drug Administration -ruter
- Medikamentell terapi
- Injeksjoner
Andre studie-ID-numre
Andre studie-ID-numre
- TQB2930-Ib/II-02
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .